Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ARQT 
Arcutis Biotherapeutics Inc (ARQT)
Top performer
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/02/2025: ARQT (5-star) is a STRONG-BUY. BUY since 100 days. Simulated Profits (85.09%). Updated daily EoD!
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.62
1 Year Target Price $31.62
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 269.34% | Avg. Invested days 39 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/02/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.72B USD | Price to earnings Ratio - | 1Y Target Price 31.62 |
Price to earnings Ratio - | 1Y Target Price 31.62 | ||
Volume (30-day avg) 7 | Beta 1.72 | 52 Weeks Range 11.13 - 31.27 | Updated Date 12/2/2025 |
52 Weeks Range 11.13 - 31.27 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.34 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.1004 | Actual 0.06 |
Profitability
Profit Margin -13.94% | Operating Margin (TTM) 8.59% |
Management Effectiveness
Return on Assets (TTM) -5.91% | Return on Equity (TTM) -28.17% |
Valuation
Trailing PE - | Forward PE 71.43 | Enterprise Value 3677091684 | Price to Sales(TTM) 11.7 |
Enterprise Value 3677091684 | Price to Sales(TTM) 11.7 | ||
Enterprise Value to Revenue 11.57 | Enterprise Value to EBITDA -2.04 | Shares Outstanding 122492192 | Shares Floating 89399701 |
Shares Outstanding 122492192 | Shares Floating 89399701 | ||
Percent Insiders 1.73 | Percent Institutions 107.59 |
Upturn AI SWOT
Arcutis Biotherapeutics Inc
Company Overview
History and Background
Arcutis Biotherapeutics, Inc. was founded in 2016. It's a biopharmaceutical company focused on developing and commercializing novel treatments for immune-mediated dermatological diseases. Significant milestones include successful clinical trials and FDA approval of Zoryve.
Core Business Areas
- Medical Dermatology: Focuses on the development and commercialization of therapies for common skin conditions such as psoriasis, atopic dermatitis, and seborrheic dermatitis.
Leadership and Structure
The leadership team consists of individuals with experience in dermatology drug development and commercialization. The organizational structure is typical of a biopharmaceutical company, with departments focused on research & development, clinical trials, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Zoryve (roflumilast) topical cream 0.3%: Zoryve is a PDE4 inhibitor indicated for the treatment of plaque psoriasis in patients 12 years and older. It's estimated to have a growing market share within the topical psoriasis treatment market. Competitors include topical corticosteroids, vitamin D analogs, and other PDE4 inhibitors like Eucrisa (crisaborole). Revenue from Zoryve is the main revenue stream. Number of users is increasing due to recent FDA approval of Zoryve for Atopic Dermatitis.
- Zoryve (roflumilast) foam 0.3%: Zoryve is a PDE4 inhibitor indicated for the treatment of seborrheic dermatitis. It is estimated to have a growing market share within the seborrheic dermatitis treatment market. Competitors include topical antifungals, topical corticosteroids, and other OTC/prescription products for seborrheic dermatitis.
Market Dynamics
Industry Overview
The dermatology market is characterized by a high prevalence of skin conditions, a growing aging population, and increasing awareness of treatment options. The market is driven by innovation in topical and systemic therapies.
Positioning
Arcutis is positioning itself as a leader in topical dermatology with a focus on PDE4 inhibition. Its competitive advantage lies in its novel formulations and efficacy data for roflumilast.
Total Addressable Market (TAM)
The global dermatology market is estimated to be billions of dollars. Arcutis is positioned to capture a significant portion of the market with its portfolio of topical roflumilast products.
Upturn SWOT Analysis
Strengths
- Novel topical formulation of roflumilast
- Positive clinical trial results
- FDA approval for plaque psoriasis and seborrheic dermatitis
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Relatively new company with limited commercial track record
- Dependence on a single product (roflumilast)
- High R&D expenses
- Potential for competition from established players
Opportunities
- Expansion into additional indications for roflumilast
- Development of new pipeline products
- Partnerships with larger pharmaceutical companies
- Geographic expansion
- Continued growth in the dermatology market
Threats
- Competition from existing therapies and new entrants
- Regulatory hurdles
- Pricing pressures
- Clinical trial failures
- Adverse events
Competitors and Market Share
Key Competitors
- VRX
- LEO
- BMY
- MRK
Competitive Landscape
Arcutis faces competition from both established dermatology companies and companies with competing mechanisms of action. Arcutis's advantage lies in its novel roflumilast formulation and indication expansion.
Growth Trajectory and Initiatives
Historical Growth: Arcutis's historical growth is characterized by clinical development progress and regulatory approvals.
Future Projections: Future growth projections would depend on the commercial success of Zoryve and the development of new pipeline products.
Recent Initiatives: Recent strategic initiatives include commercial launches of Zoryve in different formulations and focusing on life-cycle management strategies.
Summary
Arcutis Biotherapeutics is a growing company with a promising topical dermatology franchise centered around roflumilast. Zoryve's approval for psoriasis and seborrheic dermatitis is a significant achievement. While the company faces competition and relies heavily on a single product, it has the potential to grow further by expanding into new indications and developing new products. Potential clinical trial failures is a risk they need to be aware of.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Arcutis Biotherapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Industry News
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may vary. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Arcutis Biotherapeutics Inc
Exchange NASDAQ | Headquaters Westlake Village, CA, United States | ||
IPO Launch date 2020-01-31 | President, CEO & Director Mr. Todd Franklin Watanabe M.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 342 | Website https://www.arcutis.com |
Full time employees 342 | Website https://www.arcutis.com | ||
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.